Lupus & antiphospholipid syndrome
Gastrointestinal manifestations in systemic lupus erythematosus: data from an Indian multi-institutional inception (INSPIRE) cohort
Authors' conclusion
GI manifestations were observed in 9.7% of the cohort and were always associated with systemic disease activity and had higher mortality.
Study context
- Population
- Patients with SLE in a prospectively enrolled nationwide Indian cohort (INSPIRE)
- Participants
- 2,503 patients
- Exposure
- SLE with GI manifestations vs rest of the cohort
- GIn = 243
- Outcome
- Prevalence of GI manifestations
Methodological detailsmulti-institutional, nationwide, analysis of baseline database, All GI patients received immunosuppressive therapy; four required surgery
- Multi-institutional
- Nationwide
- Analysis of baseline database
- All GI patients received immunosuppressive therapy; four required surgery
Main finding
As reported in the abstract
Prevalence of GI manifestations, early in disease course · 1, 0-3 months
GI
9.7%
243
- Ascites
- 162, 6.5%
- Pancreatitis
- 35, 1.4%
- Hepatitis
- 24, 0.9%
Observational data: associations, not effects.
Further findings
Mortality
P = 0.01
Deaths and causes of death
- Patients died
- Twenty-nine (11.9%)
- Uncontrolled disease activity
- 17, 58.6%
- Infection
- 6, 20.7%
Factors associated with death in the GI group
- Lower socioeconomic class vs upper class, HR
- 2.8 (1.1-7.9) (95% CI)
- Upper lower class vs upper class, HR
- 7.5 (2-27.7)
- SLEDAI 2K, HR
- 1.06 (1.02-1.11)
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Gastrointestinal manifestations in systemic lupus erythematosus: data from an Indian multi-institutional inception (INSPIRE) cohort. Rheumatology (Oxford). Published 6 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →